SLRN: Acelyrin, Inc. Stock

by  •  • Comments Off on SLRN: Acelyrin, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 217.71
Enterprise Value ($M) 1.38
Book Value ($M) 528.28
Book Value / Share 5.27
Price / Book 0.41
NCAV ($M) 506.56
NCAV / Share 5.05
Price / NCAV 0.43

Profitability (mra)
Return on Invested Capital (ROIC) -0.49
Return on Assets (ROA) -0.36
Return on Equity (ROE) -0.40

Liquidity (mrq)
Quick Ratio 7.15
Current Ratio 7.15

Balance Sheet (mrq) ($M)
Current Assets 596.59
Assets 618.31
Liabilities 90.03
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
3 days ago 13D Tang Capital Management Llc
9 days ago 13G/A T. Rowe Price Investment Management, Inc.
9 days ago 13G/A Citadel Advisors Llc
02-10 13G/A Integrated Core Strategies (us) Llc
02-10 13D/A Access Industries Management, Llc
11-12 13G/A Vanguard Group Inc 4.07 0.00
11-08 13G BlackRock, Inc. 6.00 0.00
08-12 13G/A Fmr Llc 3.92 -55.97
03-28 13G AyurMaya Capital Management Company, LP 9.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 1,802,837 9,813,040 18.37
2025-02-20 180,609 1,603,188 11.27
2025-02-19 292,458 1,847,892 15.83
2025-02-18 352,761 2,174,532 16.22

(click for more detail)

Similar Companies
SCPH – scPharmaceuticals Inc. SDGR – Schrödinger, Inc.
SLDB – Solid Biosciences Inc. SNDX – Syndax Pharmaceuticals, Inc.
SPRO – Spero Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io